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Abstract
Aberrant cytosine methylation affects regulation of hundreds of genes during cancer development. In this study, a novel
aberrantly hypermethylated CpG island in cancer was discovered within the TOX2 promoter. TOX2 was unmethylated in
normal cells but 28% lung (n=190) and 23% breast (n=80) tumors were methylated. Expression of two novel TOX2
transcripts identified was significantly reduced in primary lung tumors than distant normal lung (p,0.05). These transcripts
were silenced in methylated lung and breast cancer cells and 5-Aza-2-deoxycytidine treatment re-expressed both. Extension
of these assays to TOX, TOX3, and TOX4 genes that share similar genomic structure and protein homology with TOX2
revealed distinct methylation profiles by smoking status, histology, and cancer type. TOX was almost exclusively methylated
in breast (43%) than lung (5%) cancer, whereas TOX3 was frequently methylated in lung (58%) than breast (30%) tumors.
TOX4 was unmethylated in all samples and showed the highest expression in normal lung. Compared to TOX4, expression of
TOX, TOX2 and TOX3 in normal lung was 25, 44, and 88% lower, respectively, supporting the premise that reduced promoter
activity confers increased susceptibility to methylation during lung carcinogenesis. Genome-wide assays revealed that
siRNA-mediated TOX2 knockdown modulated multiple pathways while TOX3 inactivation targeted neuronal development
and function. Although these knockdowns did not result in further phenotypic changes of lung cancer cells in vitro, the
impact on tissue remodeling, inflammatory response, and cell differentiation pathways suggest a potential role for TOX2 in
modulating tumor microenvironment.
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Introduction
Epigenetic inactivation of tumor suppressor genes is now
established as one of the major mechanisms leading to the
development and progression of cancer. Gene silencing through
aberrant promoter CpG island hypermethylation is the most
frequent epigenetic abnormality observed in various malignancies.
To date, a number of genome-wide screening methods have been
successfully employed to identify novel aberrantly methylated
genes in cancer. These include: restriction landmark genomic
scanning [1], CpG microarrays [2,3], methyl-CpG binding
domain chromatography [4,5] and methylated CpG island
amplification coupled with representational difference analysis
(MCA/RDA) [6]. The MCA/RDA approach has been used to
identify several methylated genes involved in colorectal [6,7,8],
pancreatic [9], prostate, and breast cancers [10]. Previously, we
used this assay to identify aberrant promoter CpG island
methylation of the PAX5 alpha and beta transcription factors in
human breast and lung cancers [11]. In this study the MCA/RDA
was used to uncover a novel aberrantly methylated CpG island
located in the promoter region of TOX2, a gene encoding for a
high mobility group (HMG)-box protein.
HMG proteins are one of the most abundant chromatin-
binding proteins that were initially characterized by high
electrophoretic mobility in polyacrylamide gel. The HMG-box
proteins are one of three classes of HMG proteins and are
characterized by one or more HMG-box (a 70–80 amino acid
DNA binding domain). Genetic and biochemical evidences
indicate that the HMG-boxes of these proteins form three a-
helices in a characteristic L-shaped structure that interacts with the
minor grove of the DNA helix to promote bending and unwinding
of compact chromatin [12,13,14]. Binding of HMG-boxes at the
minor grove also allows simultaneous binding of transcription
factors and other regulators required for DNA-based activities
such as replication, transcription and DNA repair [12,15]. The
HMG-box family proteins are often divided into two subgroups
based on their abundance and DNA binding specificity. The first
group recognizes structural features of DNA with little or no
sequence specificity, shows broad tissue distribution, and typically
contains two or more HMG-box motifs (e.g. HMGB1–4). The
second group binds DNA in a sequence specific manner, shows a
more restricted expression pattern, contains one HMG-box
domain, and consists of diverse proteins including TOX and
SOX family members [16,17,18].
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TOX (TOX1), TOX2 (GCX-1, C20orf100), TOX3 (TNRC9, CAGF9),
and TOX4 (MIG7) that share similar genomic structure and
protein homology [16]. Although the HMG-box domains of these
proteins show over 92% amino acid homology, the regions outside
this domain are less conserved indicating non-overlapping
functions. The limited functional assays available for these genes
also support this supposition. TOX (for thymocyte selection-
associated HMG-box) is primarily expressed in the thymus and
regulates the differentiation programs of developing T-cells
[19,20]. Although the function of TOX2 in humans is not yet
characterized, a rat ortholog of this gene with 100% HMG-box
domain homology (GCX-1) is primarily expressed and functions in
the hypothalamo-pitutary-gonadal axis of reproduction [21].
TOX3 is a neuronal survival factor that is highly expressed and
regulates calcium dependent transcription in neurons [22,23]. The
expression profile and specific function of TOX4 is yet known, but
this protein has been demonstrated to recognize DNA adducts
specifically generated by platinum based anticancer drugs,
suggesting it might function in DNA damage response and DNA
repair pathways [24]. However, in contrast to a growing number
of studies demonstrating abnormalities including aberrant pro-
moter CpG island hypermethylation of multiple HMG proteins in
various human malignancies, the role of TOX subfamily in
carcinogenesis is unclear [25,26,27,28,29,30,31].
The purpose of this study was to perform a genome-wide
comparison of DNA methylation between normal and tumor cells
to identify novel methylation changes in cancer. Further studies
focused on characterizing TOX2, a gene whose promoter CpG
island was found to be specifically methylated in lung and breast
cancer. The studies were also extended to other members of the
TOX subfamily that share identical gnomonic structures with
TOX2 including a similarly located CpG island. The prevalence
for aberrant methylation of these genes in primary lung and breast
tumors, specificity of methylation to cancer cells, the effects of
methylation on gene expression, and its reversibility with
demethylating and chromatin regulating drugs were evaluated.
The impact of epigenetic silencing of these genes on cancer
properties such as cell proliferation, cell death, and cell migration
were investigated. Finally, the genome-wide impact of epigenetic
inactivation of TOX subfamily genes was evaluated using specific
siRNAs to knock down individual genes, and genome-wide
transcriptome arrays were used to define the genes and pathways
affected by epigenetic silencing of this class of HMG-box proteins.
Materials and Methods
Tissue samples and cell lines
A total of 190 primary lung tumors were obtained from frozen
tumor banks at Johns Hopkins, the Mayo Clinic, and St. Mary’s
Hospital (Grand Junction, CO). Distant normal lung tissues
(DNLT) obtained from resected lung lobes of a subset of these
samples were used as normal controls. Breast tumors and adjacent
tissue were collected from women enrolled in a New Mexico
Women’s Health Study at the University of New Mexico. Non-
malignant human bronchial epithelial cells (NHBEC) and
peripheral blood mononuclear cells (PBMC) were obtained from
cancer-free smokers at the New Mexico Veteran Health Care
System. NHBEC were collected through diagnostic bronchoscopy
and expanded in short-term tissue culture as described [32]. All
samples were obtained with written informed consent from
patients, and ethical approval of the study was granted by the
Ethics Committee of the Lovelace Respiratory Research Institute.
Five normal human bronchial epithelial cell lines (HBEC1, 2, 3,
13, and 14) immortalized as described [33] were obtained from
Drs. Shay and Minna, Southwestern Medical Center, Dallas, TX.
Twenty lung cancer cell lines (H23, H1435, H1568, H1993,
H2023, H2085, H2228, H2009, H358, Calu-3, Calu-6, SKLU1,
H1299, H1838, H1975, HCC827, HCC4006, A549, SW900, and
H441), and four breast cancer cell lines (MCF-7, T47D, MDA-
MB-231, and MDA-MB-435) were obtained from and authenti-
cated by the American Type Culture Collection. Experiments
were conducted in cell lines passed for a maximum of 6 months
post-resuscitation.
MCA/RDA
The MCA/RDA assay was performed exactly as described [11]
using DNA from breast cancer cell lines (MCF-7, MDA-MB-231
and MDA-MB-435) as tester and DNA from normal breast tissue
as driver. PCR products were ligated into the PCR II vector using
the TA cloning kit (Invitrogen, San Diego, CA) and plasmid DNA
containing the RDA products were prepared using the QIAprep
Spin Miniprep kit according to the manufacturer’s instructions
(Qiagen, Valencia, CA). DNA sequencing was performed using a
Cycle Sequencing Kit (USB) and samples were analyzed on a
LICOR 4200 DNA Analyzer. Sequence homology was deter-
mined using the BLAST program of the National Center for
Biotechnology Information (www.ncbi.nih.gov/BLAST).
DNA methylation analysis
DNA extraction and modification were done exactly as
described [34] and 40 ng of modified DNA was used per PCR.
Methylation was first screened in NHBEC, PBMC, lung and
breast cancer cell lines using Combined Bisulfite Modification and
Restriction Analysis (COBRA) as described [34]. Methylation-
specific PCR (MSP), developed and optimized using cell lines with
defined methylation for each gene, was used to evaluate the
methylation status of all samples including primary lung and breast
tumors. Positive and negative control samples were included in
each MSP assay. For selected samples the density and distribution
of methylation across the CpG islands was assessed using bisulfite
sequencing. Primer sequences and amplification conditions used
for MSP, COBRA and sequencing assays are described in
supporting information Table S1.
Rapid amplification of cDNA ends (RACE)
RACE products (59 and 39) were produced using the
GeneRacer RACE Ready Lung cDNA Kit (Invitrogen) using a
2-stage nested approach as recommended. The primer sequences
and PCR amplifications conditions used for 59 and 39 RACE are
shown in supporting information Table S2. First stage 59 RACE
products were generated using the gene specific primer GSP1 and
the 59 Gene Racer anchor primer GeneRacer
TM 591 primer.
Second stage 59 RACE products were generated using the gene
specific primer GSP2 and the 59 Gene Racer nested anchor
primer GeneRacer
TM 59 Nested primer. Similarly, first stage 39
RACE products were generated using the gene specific primer
GSP3 and the 39 Gene Racer anchor primer GeneRacer
TM 39
primer. Second stage 39 RACE products were generated using the
gene specific primer GSP4 and the 39 Gene Racer nested anchor
primer GeneRacer
TM 39 Nested primer. All RACE products were
analyzed on a 3% agarose gel containing ethidium bromide,
visualized under UV illumination, cloned and sequenced.
Methylation of TOX Subfamily Genes in Lung Cancer
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treatment
Lung cancer cell lines were maintained in ATCC-recom-
mended media and cells at log-phase of growth were treated in
duplicate as described [35] using Vehicle (0.6 ml ethanol in 10 ml
medium), TSA (300 nM for 18 h [Sigma; stock solution 5 mM in
ethanol]), or DAC (500 nM for 96 h with fresh medium
containing the drug changed every 12 h [Sigma; stock solution
10 mM in PBS]). Cells treated with Vehicle or TSA underwent
fresh media changes in parallel with DAC treatment. TSA
treatment was conducted 18 h before all groups were harvested in
TRI-Reagent (Sigma).
Gene expression analysis
RNA was isolated as described [34] and 3 mg total RNA was
reverse transcribed using the High Capacity cDNA Reverse
Transcription Kit from Applied Biosystems (Foster City, CA)
according to the manufacturer’s protocol. To avoid PCR products
from contaminating DNA, RNA isolation was done in the
presence of DNase, and large introns were included in the RT-
PCR amplification product. The effect of sham (Vehicle), TSA,
and DAC treatments on gene expression was assessed using a gel-
based assay as described [35]. RT-PCR primers and amplification
conditions are described in supporting Table S1. TaqMan assays
from Applied Biosystems, TOX (Hs00207075_ml), TOX2
(Hs01031990_ml and Hs01040060_ml), TOX3 (Hs01101330_ml),
TOX4 (Hs00927393_ml), and the housekeeping gene beta-actin
(4310881E), were used for quantitative gene expression analysis.
Each target gene was run at least twice in duplicate and the DCT
values were generated from the housekeeping gene multiplexed in
each reaction as the endogenous control. The DDCT values were
generated by comparing the reference samples to the test group,
that is DNLT vs. primary tumors, and vehicle treated cell lines
(control siRNA or vehicle) vs. cell lines treated with gene-specific
siRNA or drugs (TSA or DAC) depending on the experiment. The
relative gene expression levels were then calculated using the
DDCT method as described [36].
Gene knock down and genome-wide expression analysis
Cell lines that are confirmed to express the gene of interest,
MDA-MB-231 (TOX), Calu-3 and MDA-MB-231 (TOX2), and Calu-
3 and MCF-7 (TOX3) were transfected with negative control #1
(siControl) or gene-specific siRNAs, TOX s18842 (siTOX), TOX2
s39780 (siTOX2), or TOX3 s26152 (siTOX3) all from Applied
Biosystems using Lipofectamine 2000 (Invitrogen, Santa Clara,
CA). The impact of epigenetic down regulation of these genes on
cell properties that include proliferation, cell death, and migration
were compared between cells transfected with gene-specific or
control siRNA using MTT and wound closure assays as described
[37]. For genome-wide expression assays, cells were harvested
48 h post-transfection, gene knockdown was confirmed by Taq-
Man, and changes in gene expression was compared between
siControl vs. siTOX2 and siControl vs. siTOX3 cells using the Agilent
whole genome transcriptome array as described [35].
Data analysis
Gene methylation and patient characteristics including age,
gender, smoking status, tumor histology, and performance were
summarized with mean and standard deviation for continuous
variables and proportions for categorical variables. Survival time
was calculated from time of diagnosis until death from any cause
or last follow-up. The association between methylation and patient
characteristics was assessed by Fisher’s exact test. Kaplan-Meier
plots, the log-rank test, and proportional hazards models were also
employed. The effect of siRNA knockdown (siControl vs. siTarget
gene) on gene expression was compared using one way analysis of
variance (ANOVA). Tukey’s and Dunnett’s method were used for
pair wise and treatment control comparison adjustments, respec-
tively. The impact of potential outliers on the one way ANOVA
values was controlled using nonparametric Wilcoxon Rank-sum
test.
Results
MCA/RDA identifies a novel aberrantly methylated CpG
island in cancer
Previously, we used the MCA/RDA technique developed by
Toyota et al [6] to discover aberrant promoter hypermethylation of
two transcription factor genes, PAX5 a and b, in human tumors
[11]. Two other clones simultaneously discovered with the PAX5
clone were homologous to the GenBank accession number
AL035089, and map to chromosome 20q12-13.2 adjacent to each
other at nucleotides 161, 665–161,987 and 161,982–162,220.
They represent two consecutive 323 and 239 bp DNA segments
that are flanked by three CCCGGG sequences, recognition sites
for SmaI and XmaI restriction enzymes used in the MCA/RDA
assay. These sequences were found to be hypermethylated in the
breast cancer cell line (MDA-MB-231), but not in normal breast
tissue. GenBank report for accession number AL035089 indicates
the presence of a CpG island extending from nucleotide 160,344
to 162,383. This CpG island is GC-rich (0.71) with a CpG:GpC
ratio of 0.9, contains 216 CpGs, and is located in a typical
promoter CpG island location spanning 2394 to +1646 bp from
the transcription start site of a gene encoding for a TOX high
mobility group box protein, TOX2.
TOX2 promoter is hypermethylated in lung and breast
tumors
The presence and degree of methylation within TOX2 promoter
CpG island was first screened in lung and breast cancer cell lines
using COBRA. Methylation was found in 4/20 (20%) lung cancer
cell lines and 3/4 (75%) breast cancer cell lines (Table 1). In
contrast, primary human bronchial epithelial cells (NHBEC)
obtained from bronchoscopy of cancer free smokers (n=20), five
human bronchial epithelial cell lines (HBEC) immortalized as
described [33], peripheral blood mononuclear cells (PBMC)
obtained from cancer free donors (n=10), and distant normal
lung tissue (DNLT) obtained from NSCLC patients (n=8) were
unmethylated (Table 1 and Figure 1A). For selected samples the
degree and distribution of methylation across the TOX2 promoter
CpG island was determined through bisulfite sequencing. The
sequencing data validated results obtained through COBRA and
MSP (not shown) assays and also revealed that the distribution of
methylation across the 51 CpGs analyzed was mostly uniform
(Figure 1B). Among primary tumors, TOX2 methylation was
detected in 28% (54/190) lung and 23% (18/80) breast tumors
(Table 1). The prevalence for methylation of TOX2 in lung cancer
was similar between adenocarcinoma and squamous cell carcino-
ma. Interestingly, TOX2 methylation among lung adenocarcinoma
patients was significantly more prevalent in tumors from current
smokers 43% (16/37) compared to never smokers 24% (18/75) or
current non-smokers (former and never smokers combined) 26%
(35/134) (p,0.05). Although not statistically significant, TOX2
methylation in lung adenocarcinoma from current smokers was
also higher than former smokers (43% vs. 29%, p=0.15) (Table 1).
Methylation of TOX Subfamily Genes in Lung Cancer
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The primary reference sequence for Homo sapiens chromosome
20, GRCh37.p2, (accession number NC_000020.10) predicted
(based on automated computational gene prediction methods) four
protein coding TOX2 transcripts [38,39]. To define the transcripts
expressed in lung and breast tissue, 59 RACE using a set of nested-
antisense PCR primers (GSP1 and GSP2) complimentary to
regions within exon-2 (present in all four predicted transcripts) was
applied (Figure 2A). Following two rounds of amplification, a
single 165 bp fragment was generated, cloned, and sequenced.
Analysis of five clones revealed that the sequence was similar to the
first two exons (exon 1 and 2) of the predicted TOX2 var.1
(GenBank accession number NM_001098797.1). The remaining
three transcript variants predicted to comprise exons 1a (var.4), 1b
(var.2), or 1a and 1c (var.3), GenBank accession numbers
NM_001098798.1, NM_032883.2, and NM_001098796.1, re-
spectively, were not detected (Figure 2A). The complete sequence
of the transcripts were determined through 39 RACE using a
second set of nested-PCR primers complimentary to regions in
exon 1 (GSP3) and exon 2 (GSP4). The 39 RACE produced two
transcripts that were confirmed by sequencing and RT-PCR. The
longer (2314 bp) of these transcripts (designated TOX2 var.5) was
similar, except at exon 7, to TOX2 var.1. Exon 7 in var.1 was
predicated to have 396 bp sequence. But in TOX2 var.5, only the
59 half (198 bp) of this exon was spliced to exon 8, indicating a
novel transcript variant distinct from var.1 (Figure 2A). The
second transcript (designated TOX2 var.6) was 1213 bp and
consists of three exons (exon 1, 2, and 3). While exon 1 and 2 were
similar to transcript var.5, exon 3 was extended further by an
additional 752 bp including a stop codon at nucleotides 289–291.
In contrast to var.5 as well as any of the four predicted transcripts,
TOX2 var.6 lacks exons 4–9 including the sequences within exons
5 and 6 that encode for the characteristic DNA-binding HMG-
box domain (Figure 2A). The complete sequences of the two novel
transcripts have been deposited at GenBank [accession numbers
JN655166 (TOX2 var.5) and JN655167 (Tox2 var.6)] and are
shown in supporting Figures S1A and B.
TOX2 methylation is associated with gene silencing
Both TOX2 transcript variants (var.5 and var.6) were expressed
in DNLT and normal bronchial epithelial cells (first 6 lanes of
Figure 2B). Quantitative analysis of these transcripts in paired
tumor-normal tissues obtained from NSCLC patients revealed
that both transcripts were significantly reduced in lung tumors
compared to normal lung (Figure 2C). The relationship between
hypermethylation of TOX2 promoter and expression of the two
transcripts was compared in normal and malignant cell lines. In
HBEC and the lung cancer cell lines H1299 and SKLU1 with
unmethylated TOX2 promoter CpG island (Figures 1A and 1B),
both TOX2 transcripts were expressed at levels similar to DNLT
(Figure 2B). In contrast, both transcripts were silenced in lung
(H1838 and H2009) and breast (T47D) cancer cell lines in
conjunction with densely methylated promoter CpG islands. In
MDA-MB-231 (M-231), the presence of some undigested PCR
products in the COBRA assay (Figure 1A) and the absence of
methylation in 2 out of 5 bisulfite sequenced clones (nearly all 51
CpGs in clones 1 and 5 are unmethylated, Figure 1B) indicate that
the TOX2 promoter is hemi-methylated in this cell line. In
agreement with this, both transcripts of TOX2 were expressed in
MDA-MB-231 (Figure 2B).
DAC treatment restores TOX2 expression
Lung and breast cancer-derived cell lines with or without TOX2
promoter hypermethylation were treated with Vehicle (S for
sham), the DNA demethylating agent 5-Aza-29-deoxycytidne
(DAC), or the histone deacetylase inhibitor trichostatin A (TSA)
as described to evaluate the contribution of cytosine methylation
and chromatin remodeling in silencing this gene. Expression of
both TOX2 transcripts could be restored in H1838 and H2009
Figure 1. Methylation of TOX2 promoter CpG island. A) Combined bisulfite modification and restriction analysis (COBRA) depicts methylation
of TOX2 promoter CpG island in normal and cancer samples. Complete, partial, or no methylation could be seen from digestion of all, some, or none
of the PCR products in the presence of the BstU1 (+) enzyme compared to no enzyme (2) control. MDA-MB-231 and MDA-MB-435 in all the figures
are abbreviated as M-231 and M-435, respectively. B) Bisulfite sequencing was used to validate methylation results obtained through COBRA and MSP
assays and to determine the degree and distribution of methylation at 51 CpG sites across TOX2 promoter CpG island. Five clones were sequenced
per sample and methylation status of each clone (1/5
th of a circle) at the specified CpG site is shown as methylated (filled) or unmethylated (open).
doi:10.1371/journal.pone.0034850.g001
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partially restore expression of transcript var.6 but not var.5 in
T47D. Quantitative analysis of these transcripts using TaqMan
primer-probe sets that are distinct from the primers used for the
gel-based assays confirmed these findings and showed that DAC
treatment led to 39–227- and 7–73-fold increased expression of
both transcripts or var. 5 alone, respectively (Figure 2D). TSA
treatment had little or no effect on the expression of these
transcripts (Figure 2B and 2D). In cell lines with unmethylated or a
hemi-methylated TOX2 promoter, both transcripts were detected
in vehicle treated cells and treatment with either TSA or DAC had
little or no effect on the expression of these transcripts (Figure 2B
and 2D).
Distinct methylation of TOX subfamily genes between
lung and breast tumors
The TOX subfamily in human includes three additional
members (TOX, TOX3, and TOX4) that share similar genomic
structure with TOX2 including conserved intron/exon boundaries,
high protein homology, and a similarly located promoter CpG
island (Table S3). Thus, these genes are considered to arise
through gene duplication [16]. The DNA-binding HMG-box
motif of TOX2 is nearly identical (92, 94, and 94% homology) to
that of TOX, TOX3, and TOX4, and overall the three proteins,
respectively share 59, 65, and 62% amino acid homology to
TOX2. These similarities and the discovery of aberrant methyl-
ation of TOX2 in lung and breast tumors prompted us to evaluate
the methylation status of the remaining TOX subfamily genes. The
promoter CpG islands of TOX and TOX3 were also methylated in
20 and 25% lung, and 75 and 50% breast cancers cell lines,
respectively (Table 1). In contrast, the promoter CpG island of
TOX4 was unmethylated in all lung and breast cancer cell lines,
and none of these genes were methylated in normal tissue
(NHBEC, HBEC, PBMC, and DNLT). Among primary tumors,
TOX and TOX3 were methylated in 5% (9/190) and 58% (110/
190) lung and 43% (34/80) and 30% (24/80) breast tumors,
respectively (Table 1). Interestingly, the prevalence for TOX3
methylation among lung cancer patients was significantly greater
in squamous cell carcinoma 79% (15/19) compared to adenocar-
cinoma 56% (95/171). The level of expression of TOX subfamily
genes in DNLT were inversely correlated with the prevalence for
methylation of primary tumors (Figure 3A). Compared to TOX4,
expression of TOX, TOX2, and TOX3 in normal tissue was
reduced by 25, 44, and 88%, respectively.
Tumor-specific hypermethylation of TOX in breast tumors but
not in the adjacent normal tissue has been recently demonstrated
as a potential novel tumor biomarker [10]. Our data revealed that
TOX is hypermethylated in 43% of breast tumors and further
studies demonstrated that expression of this gene in breast cancer
cells is epigenetically silenced. TOX is completely (MCF-7 and
MDA-MB-435) or partially (T47D) methylated in three out of four
breast cancer cell lines (Figure 3B). As shown in Figure 3C (top left)
expression of TOX in the methylated cell lines (including the
weakly methylated T47D) is dramatically reduced compared to the
unmethylated cell line (MDA-MB-231). Treatment with either
TSA or DAC led to partial re-expression of TOX in the methylated
breast cancer cell lines (Figure 3C). Consistent with the minor
methylation seen in T47D (Figure 3B), treatment with TSA
resulted in ,20-fold increased expression, more than the ,5-fold
increase seen after DAC treatment (Figure 3C, bottom left). To
evaluate the impact of methylation-mediated silencing of TOX in
breast cancer, MDA-MB-231 cells where the gene is unmethylated
and abundantly expressed were transfected with control (siCon-
trol) or TOX specific (siTOX) siRNAs. Although TOX expression
in siTOX transfected cells was reduced by 75% compared to the
siControl, it did not significantly affect the proliferation (measured
by MTT, not shown) or migration potential of the cells (Figure 3D).
TOX3 is silenced by promoter hypermethylation
The level and distribution of methylation across the TOX3
promoter CpG island and its impact on the expression of this gene
was evaluated as described for TOX2. COBRA (Figure 4A) and
bisulfite sequencing of 58 CpGs within the TOX3 promoter CpG
island (Figure 4B) revealed that TOX3 is unmethylated in all
normal samples and some lung and breast cancer cell lines.
However, these assays also revealed dense methylation of TOX3
promoter in some lung and breast cancer cell lines. With the
exception of HBEC1, TOX3 expression was readily detected in all
unmethylated samples including normal lung tissue, HBEC2, as
well as lung and breast cancer cell lines with unmethylated TOX3
promoter such as H1838 and T47D (Figure 4C). In contrast,
TOX3 expression was completely silenced in sham (S) lung and
breast cancer cell lines with dense promoter methylation such as
H1299, SKLU1, H2009, and MDA-MB-231 (Figures 4A–C). With
the exception of H2009, TOX3 expression in the methylated cell
lines was mostly restored after DAC treatment (Figure 4C).
Quantitative TaqMan assays using primer probes distinct from
those used for the gel-based assays also reproduced the observed
re-expression of TOX3 after DAC treatment (Figure 4D).
Table 1. Prevalence for promoter CpG island
hypermethylation of TOX subfamily of genes.
Sample Type Methylated (%)
TOX TOX2 TOX3 TOX4
Normal tissue
NHBEC 0/20 (0) 0/20 (0) 0/20 (0) 0/20 (0)
HBEC 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0)
PBMC 0/10 (0) 0/10 (0) 0/10 (0) 0/10 (0)
DNLT 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0)
Breast cancer
Cell lines 3/4 (75) 3/4 (75) 2/4 (50) 0/4 (0)
Primary tumors 34/80 (43)
A 18/80 (23) 24/80 (30)
A ND
Lung cancer
Cell lines 4/20 (20) 4/20 (20) 5/20 (25) 0/20 (0)
Primary tumors 9/190 (5) 54/190 (28) 110/190 (58) ND
Adenocarcinoma 7/171 (4) 51/171 (30) 95/171 (56) ND
Current smokers 1/37 (3) 16/37 (43)
B 18/37 (49) ND
Former smokers 4/59 (7) 17/59 (29) 29/59 (49) ND
Never smokers 2/75 (3) 18/75 (24) 48/75 (64)
C ND
Squamous cell
carcinoma
2/19 (11) 3/19 (16) 15/19 (79)
D ND
AMethylation of TOX was significantly more prevalent in breast than lung tumor
(p,0.001). In contrast, TOX3 methylation was more common in lung than
breast tumor (p,0.001).
BAmong NSCLC patients, the prevalence for TOX2 methylation in current
smokers was significantly higher than never smokers (p,0.05) as well as current
non-smokers (former and never smokers combined) (p,0.05).
CTOX3 methylation in primary lung tumors was marginally more prevalent in
never smokers compared to current or former smokers (p=0.05).
DTOX3 methylation in primary lung tumors was more prevalent in squamous
cell carcinoma compared to adenocarcinoma (p=0.05).
doi:10.1371/journal.pone.0034850.t001
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multiple genes
The impact of promoter methylation-mediated silencing of
TOX2 and TOX3 was similarly investigated in vitro using siRNAs
targeting the two genes. Lung (Calu-3 for both genes) and breast
cancer cell lines (MDA-MB-231 for TOX2 and MCF-7 for TOX3)
where the two genes are expressed were selected for transfection.
Quantitative TaqMan assays confirmed that compared to control
siRNA (siControl), transfections with siTOX2 and siTOX3
reduced expression of TOX2 (both transcripts) and TOX3 by 70–
86% (Figure 5A and 5B). Similar to TOX, MTT and wound
closure assays revealed that knock down of either of these genes
Figure 2. TOX2 expression in normal and cancer cells. (A) Genomic structure of TOX2. Top box: Predicted transcript variants of TOX2 (var.1-4)
currently used as reference sequence for Homo sapiens chromosome 20, GRCh37.p2, (GenBank accession number NC_000020.10). Bottom box:
Transcripts sequenced from human cells (var.5 and 6). Small arrows indicate the location and direction of primer binding sites; T#Fo rT #R (forward
or reverse primers for TaqMan assays) and G#Fo rG #R (forward or reverse primers for gel-based assays). (B) Expression of TOX2 transcript variants 5
and 6 and the house keeping gene beta-actin in distant normal lung tissue (DNLT), HBEC, and various lung and breast cancer cell lines. In Vehicle-
treated (S, for sham) lung cancer (H1838, H2009) and breast cancer (T47D) cell lines with methylated promoter CpG island, both transcripts were
silenced and expression of both was primarily restored with 5-Aza-29-deoxycytidne (D) but not trichostatin A (T) treatment. (C and D) TaqMan assays
that use distinct primer sets from those used for gel-based assays confirmed results shown in Figure 2B. (C) Expression of TOX2 var.5 or both (var.5 &
6) in lung tumors (n=20) relative to DNLT (n=10) obtained from NSCLC patients. (D) Expression of TOX2 var.5 or both (var.5+6) in TSA or DAC treated
lung and breast cancer cell lines relative to Vehicle-treated (Sham) cell lines.
doi:10.1371/journal.pone.0034850.g002
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of lung or breast cancer cells (Figure 5C and 5D).
The potential impact of epigenetic inactivation of TOX2 and
TOX3 on genes and pathways across the genome was evaluated
using a genome-wide transcriptome array conducted on Calu-3
cells transfected with siControl, siTOX2, or siTOX3. This
genome-wide expression array revealed knockdown of TOX2
affected the expression of 830 genes (437 increased and 393
decreased) by more than 1.5-fold and significantly modified
multiple pathways including tissue remodeling, mitogenic signal-
ing, inflammatory and immune responses, apoptosis, cell cycle
regulation and differentiation, and multiple regulatory pathways of
the circulatory system (Figure 5E). Genes that showed $2-fold
increased (73) or decreased (71) expression after TOX2 knockdown
are listed in supporting Table S4 and S5. Despite affecting the
expression of hundreds of genes and modulating multiple
pathways, TOX2 knockdown did not impact cell proliferation,
cell death, cell migration or growth in soft agar of Calu-3 cells (not
Figure 3. Relative expression of TOX subfamily genes in normal lung tissue. (A) Expression of each gene was quantified using TaqMan
assays and the level of TOX4, which is unmethylated in all samples and expressed the highest in normal lung tissue, was used as a reference to
calculate the relative level of the remaining genes. * p=0.03, ** p,0.001, *** p,0.0001 compared to TOX4.( B) COBRA conducted as described for
Figure 1A. (C) TOX expression was measured relative to its expression in MCF-7 (Top left) or vehicle treated MDA-MB-231 (M-231), T47D,o rMCF-7.( D)
Transfection of M-231 with siTOX reduced its expression by 75% compared to siControl (left) but this did not alter the migration potential of the cells.
doi:10.1371/journal.pone.0034850.g003
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inactivation, TOX3 knockdown resulted in more specific changes
targeting genes involved in neuronal development. Overall, TOX3
knockdown affected the expression of 275 genes by $1.5 fold (50
increased and 225 decreased) and significantly modulated
synaptogenesis and axonal guidance pathways (Figure 5F). Genes
with $2-fold increased (7) or decreased (27) expression after
siRNA-mediated TOX3 silencing are shown in Table S6. Similar
to TOX2, TOX3 knockdown also did not significantly altered cell
proliferation, cell death, or migration properties of Calu-3 cells
(not shown).
Discussion
This study identified for the first time aberrant hypermethyla-
tion of the TOX2 promoter CpG island in cancer and
characterized its potential contribution to carcinogenesis. Two
novel transcripts of TOX2 that are distinct from variants predicted
Figure 4. Methylation and expression of TOX3 in lung and breast cancer. (A) COBRA and (B) bisulfite sequencing assays were used to assess
the methylation status of TOX3 and the results are summarized as described for figure 1. (C) Expression of TOX3 and beta-actin in DNLT, HBEC, and
various lung and breast cancer cell lines. TOX3 was silenced in vehicle-treated (S) lung cancer (H1199, SKLU1, and H2009) and breast cancer (MDA-MB-
231, abbreviated as M-231) cell lines with methylated promoter CpG island. Treatment with 5-Aza-29-deoxycytidne (D) but not trichostatin A (T)
restored TOX3 expression. (D) Quantitative analysis of TOX3 in lung and breast cancer cell lines treated with Vehicle (Sham), TSA, and DAC using a
TaqMan assay that uses primer sets distinct from the primers used for gel-based assays confirmed results shown in figure 3C.
doi:10.1371/journal.pone.0034850.g004
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TOX2 promoter silenced both of these transcripts in lung and
breast cancer cells and DAC treatment restored expression of both
transcripts in vitro confirming epigenetic regulation. Expression of
both transcripts was significantly lower in primary lung tumors
compared to distant normal lung tissue. Extension of these assays
to other members of TOX subfamily genes that share similar
genomic structure and protein homology to TOX2 revealed
distinct methylation profiles between lung and breast tumors.
Methylation of TOX was almost exclusively seen in breast cancer,
whereas TOX3 methylation was more prevalent in lung than
breast cancer. Furthermore, the genome-wide impact of epigenetic
inactivation assessed by siRNA revealed that TOX2 knockdown
modulated multiple molecular pathways including important
modulators of tumor microenvironment such as tissue remodeling,
inflammatory response, and cell differentiation. In contrast, TOX3
knockdown specifically targeted pathways involved in neuronal
development and axonal guidance, recently defined functions of
TOX3 [22,23]. Although knockdown of either gene by siRNA did
not alter cell proliferation, survival, or migration significantly, the
differential methylation profile of TOX subfamily genes across
tumor type and histology and the genes and pathways affected by
epigenetic silencing of these genes could be exploited for
developing tumor-type specific biomarkers [10,40].
The four transcript variants currently used as the primary
reference sequence for TOX2 in Homo sapiens are predicted
sequences generated through automated computational gene
prediction methods [38,39]. This study provides the first
experimentally generated transcripts of TOX2 that were cloned
and sequenced from normal and malignant lung and breast tissue.
The amino acid sequence deduced from one of these transcripts,
TOX2 var.5, is over 93% homologous to the granulosa cell HMG-
Figure 5. Genome-wide impact of epigenetic inactivation of TOX2 and TOX3. Transfection of (A) Calu-3 and MDA-MB-231 (M-231) with
siRNAs targeting TOX2 (siTOX2)o r( B) Calu-3 and MCF-7 targeting TOX3 (siTOX3) reduced expression of these genes by 70–86% compared to cells
transfected with control siRNA (siControl). (C and D) However, knockdown of these genes did not change the migration potential of these cells.
Genome-wide gene expression assays comparing Calu-3 cells transfected with (E) siControl vs. siTOX2 or (F) siControl vs. siTOX3 revealed genes and
pathways modulated by epigenetic inactivation of these genes.
doi:10.1371/journal.pone.0034850.g005
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granulosa cell cDNA library [21]. GCX-1 is a potent transcrip-
tional activator exclusively expressed in the hypothalamo-pitui-
tary-gonadal axis of Wistar rats, and functions as a specific
regulator of follicular development and other events related to
reproduction [21]. The perfect homology (100%) between the
HMG-box domains of TOX2 var.5 (human) and GCX-1 (rat)
indicates this gene is highly conserved across the two species and
suggests that the protein encoded by TOX2 var.5 in humans may
similarly function as a transcription factor [21]. In contrast, TOX2
var.6 does not encode for the characteristic DNA binding HMG-
box domain suggesting that the protein encoded by this variant
may not directly bind to DNA and potentially could serve as a
negative competitor to the remaining TOX2 variants. Expression
of these transcripts in normal lung suggests TOX2 may have
different or additional functions in humans, thus further studies
are required to define the tissue distribution and specific roles of
these TOX2 variants.
It is now well established that cancer cells accumulate aberrant
methylation of hundreds of genes [41]. Emerging evidence from
genome-wide and candidate gene methylation studies indicate that
the methylation profile of some of these genes could discriminate
tumors by phenotypes such as cancer-type, histology, and stage of
disease [10,40]. In this regard, the differential methylation of TOX
and TOX3 between lung and breast cancer, TOX2 across cigarette
smoking habit, and TOX3 by the histology of lung cancer suggest,
methylation of TOX subfamily genes could be important
biomarkers for cancer profiling. In agreement with our findings,
a recent study after evaluation of leukemia and various solid
tumors including prostate, colorectal, breast, and liver cancers,
also identified TOX methylation as important biomarker specifi-
cally for breast cancer [10]. Interestingly, this study also used the
MCA/RDA assay to identify methylation of TOX, among other
genes, and reported exactly similar methylation of TOX in 3/4
(75%) breast cancer cell lines (3 of the cell lines are different from
those used in our study) and 10/24 (42%) in primary breast
tumors.
Although the cause of differential methylation patterns among
cancer types is not well defined, different susceptibility of CpG
islands for methylation, which also varies by cell/tissue type, is
considered to play a major role. Not all CpG islands are equally
susceptible for methylation during carcinogenesis and one of the
prominent factors associated with susceptibility/resistance of
promoter CpG island methylation is the level of promoter activity.
CpG islands in the promoter region of housekeeping and other
constantly expressed genes are often protected from methylation.
In contrast, CpG islands within non-coding sequences, repetitive
elements, and promoter regions of tissue specific genes with lower
gene activity are prone to methylation [42]. Although direct
evidence linking transcription factor binding to promoter region
with protection from methylation is yet to be established, the role
of transient reduction in gene expression as a trigger for
methylation has been demonstrated [43]. In agreement with this
supposition, the level of expression of TOX subfamily genes in
normal lung was inversely related to the prevalence for
methylation in lung tumors. TOX3, which has the most commonly
methylated promoter CpG island in lung tumors (58%) was
expressed at the lowest level in normal lung. Conversely,
expression of TOX4, which is unmethylated in all samples
analyzed, was the highest in normal lung. The fact that the
expression patterns and functions of TOX subfamily genes vary
across tissue types also support different susceptibility to
methylation leading to tumor-specific methylation profile.
TOX is highly expressed in the thymus and plays a critical role
in T-cell selection, differentiation, and maturation [20]. Whereas
TOX3 is a neuronal survival factor that regulates Ca
2+-dependent
transcription in neurons [22,23]. Consistent with this function, our
data also revealed that epigenetic inactivation of TOX3 specifically
modulates pathways involved in synaptogenesis and axonal
guidance. A recent study revealed that TOX4 is recruited to
DNA-damage specifically induced by platinum compounds
(cisplatin and oxaliplatin but not UV) indicating a potential role
in DNA damage and repair [24]. Currently, there is no data
regarding the normal function of TOX2. GCX-1, the rat ortholog
of TOX2, is a potent transcriptional activator involved in the
hypothalamo-pitutary-gonadal axis of reproduction [21]. Howev-
er, due to a specified approach of the study, the expression and
function of GCX-1 in rat lung and mammary tissue is unclear.
Our data show that TOX2 is expressed in human lungs and
epigenetic inactivation of this gene in lung cancer modulates
multiple pathways. Among these pathways the involvement of
tissue remodeling, inflammatory response, cell differentiation,
apoptosis, cell cycle regulation, and DNA-damage response in
carcinogenesis is well established, substantiating a role for TOX2
in contributing to early malignant changes and modulation of the
tumor microenvironment in vivo.
Supporting Information
Figure S1 Sequences of TOX2 transcript variants iden-
tified in this study. Two novel transcript variants of TOX2 that
are unique from any of the predicted transcripts were identified.
(A) cDNA sequence of transcript variant 5 is largely similar to the
predicted TOX2 var.1 (Accession number NM_001098797.1)
except the 39 half (186 bp) of exon-7 is missing in var.5. A
sequence variation at position 140, where a T nucleotide was
missing in TOX2 var.5 was also found. (B) cDNA sequence of the
second novel transcript variant (TOX2 var.6) identified in this
study was similar to TOX2 var.5 up to exon-3, including the single
nucleotide variation at position 140. However, exon-3 was
extended further by 754 nucleotides including a stop codon at
nucleotide positions 289–291 bp. The sequence of this additional
component of exon-3 was similar (other than a C to T variation at
nucleotide 1047) to the genomic sequence of TOX2 (Accession
number NC_000020.10). Sequence variations seen in the two
novel transcripts (a TT instead of TTT in var.5 and a C to T in
var.5) are highlighted, and translation start and stop codons are
shown in bold and underlined. These two nucleotide sequences
are deposited at GenBank and have been provided GenBank
accession numbers JN655166 for TOX2 var.5 and JN655167 for
Tox2 var.6.
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